An Observational Study on Bevacizumab (Avastin) as First-Line Treatment in Colorectal Cancer Participants With Potentially Resectable Liver Metastases

Sponsor
Hoffmann-La Roche
Study ID
NCT01343901
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab — DRUG
    Participants with mCRC and having exclusively liver or liver and lung metastases who were receiving bevacizumab as part of first line treatment for potentially resectable liver metastases as per treating physician's discretion will be observed. All concomitant medications as used in routine clinical practice are allowed.

Study Details

This observational study will evaluate the efficacy and safety of bevacizumab as first-line treatment in participants with colorectal cancer and potentially resectable liver metastases.

Key Dates

First listed
Apr 28, 2011
Start date
Sep 30, 2010
Status verified
Mar 2017
Primary completion
Jun 30, 2015
Completion
Jun 30, 2015

Study Design

Enrollment
210 participants (actual)

Arms

  • Arm: Bevacizumab
    Participants with metastatic colorectal cancer (mCRC) with exclusively liver or liver and lung metastases, who were receiving bevacizumab as part of first line treatment for potentially resectable liver metastases will be observed.

Primary Outcome Measure

Percentage of Participants Without Detectable Metastatic Disease After Secondary Resection Post Surgery [ Time Frame: Baseline up to 36 months ]

Related Studies